MELISSA MASON: Open Payments
NPI 1932796331 · BELLEVUE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,081 in 41 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $1,417 · 2025 $1,081
Food & beverage: $1,081
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 9 | $286 |
| E.R. Squibb & Sons, L.L.C. | 4 | $164 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $159 |
| Otsuka America Pharmaceutical, Inc. | 7 | $137 |
| Alkermes, Inc. | 5 | $115 |
| ABBVIE INC. | 3 | $92 |
| Neuronetics, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Lundbeck LLC | 2 | $32 |
| Bausch Health US, LLC | 1 | $20 |
Products named: Auvelity, REXULTI, COBENFY, CAPLYTA, VRAYLAR, LYBALVI, ARISTADA, NEUROSTAR TMS THERAPY SYSTEM.
Industry payments across WA — which companies pay providers there.
